Medicines repurposing project launched in Europe

Generics/General | Posted 21/01/2022 post-comment0 Post your comment

In late October 2021, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) announced the launch of a pilot project to support the repurposing of medicines.

109 MD002387

This European drug repurposing project comes as a follow-up to discussions held by the European Commission’s Expert Group on Safe and Timely Access to Medicines for Patients (STAMP), on medicines repurposing and the development of a European medicines repurposing framework [1].

The pilot project aims to support not-for-profit organizations and academia in providing adequate evidence on the use of established medicines in new indications. This initiative hopes to make new treatment options available to patients without the need to develop new products.

Together, EMA and national medicines agencies will provide regulatory support, scientific advice, and offer fee waivers and other support to organizations exploring new uses for existing drug products. They will also connect these organizations with pharmaceutical partners to seek marketing authorization.

It has been outlined that candidate medicines for the pilot should contain a well-established active substance and be an authorized medicine out of data exclusivity and market protection periods. The candidate must also target an indication in a condition distinct from the currently authorized indication(s) and one that is in an area where important public health benefits are achievable.

The pilot will focus on conditions for which no or few medicines are currently authorized or conditions which currently have an associated high morbidity and/or mortality.

Related articles
Technological approaches to drug repurposing for cancer treatment

Europe calls for more drugs repurposing

Value-added medicines: how repurposed medicines bring value to patients and pharmacists


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Europe calls for more drugs repurposing []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010